Prefrontal connections express individual differences in intrinsic resistance to trading off honesty values against economic benefits by Dogan, Azade et al.
1Scientific RepoRts | 6:28755 | DOI: 10.1038/srep28755
www.nature.com/scientificreports
Next generation sequencing based 
identification of disease-associated 
mutations in Swiss patients with 
retinal dystrophies
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Niklas Winkler2, Daniel Barthelmes2, Lieselotte Berger3, Christina Gerth-Kahlert2,  
John Neidhardt1,‡,# & Wolfgang Berger1,4,5
Inherited monogenic diseases of the retina and vitreous affect approximately 1 in 2000 individuals. They 
are characterized by tremendous genetic heterogeneity and clinical variability involving mutations in 
approximately 250 genes and more than 20 different clinical phenotypes. Clinical manifestations of 
retinal dystrophies (RDs) range from mild retinal dysfunctions to severe congenital forms of blindness. 
A detailed clinical diagnosis and the identification of causative mutations are crucial for genetic 
counseling of affected patients and their families, for understanding genotype-phenotype correlations 
and developing therapeutic approaches. Using whole exome sequencing (WES) we have established 
a reliable and efficient high-throughput analysis pipeline to identify disease-causing mutations. Our 
data indicate that this approach enables us to genetically diagnose approximately 64% of the patients 
(n = 58) with variant(s) in known disease-associated genes. We report 20 novel and 26 recurrent variants 
in genes associated with RDs. We also identified a novel phenotype for mutations in C2orf71 and provide 
functional evidence for exon skipping due to a splice-site variant identified in FLVCR1. In conclusion, 
WES can rapidly identify variants in various families affected with different forms of RDs. Our study also 
expands the clinical and allelic spectrum of genes associated with RDs in the Swiss population.
Monogenic retinal dystrophies (RDs) account for vision loss in more than 2 million people worldwide1. The 
genetic basis of RDs is extremely heterogeneous. Mutations in approximately 250 genes are currently known to be 
responsible for over 20 different clinically distinguished phenotypes. Clinical manifestations for these disorders 
range from mild dysfunctions (such as night blindness) to severe and early onset RDs (such as Leber congenital 
amaurosis, LCA). Retinitis pigmentosa (RP) is the most common form of familial RDs affecting 1 in 3500–4000 
people. It affects predominantly the rod photoreceptors and can be transmitted in an autosomal recessive (arRP), 
dominant (adRP) or an X-linked mode of inheritance (XlRP)1,2. arRP is considered more severe in terms of a 
younger age of onset and faster disease progression and accounts for over 50–60% of all RP cases. adRP usually 
is less severe, accounts for 30–40% of RP cases and is associated with a later age of onset1,2. In addition, incom-
plete penetrance has been described for a number of dominant gene mutations3–6. XlRP is seen in 5–15% of RP 
cases2. Clinical manifestations in RP typically begin with night blindness. Later, during disease progression, tun-
nel vision is characteristic and the disease may in some cases lead to complete blindness. Cone dystrophies (COD) 
and cone-rod dystrophies (CORD) are more severe compared to rod-dominated phenotypes1. The age of onset is 
usually during early adult life. So far there are 33 genes known to be involved in COD or CORD (RetNet: https://
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sph.uth.edu/retnet/home.htm). Mutations in the respective genes are autosomal dominant or recessive as well as 
X-linked. LCA is one of the most severe forms of RDs involving rod and cone photoreceptor cells. Patients usually 
present at birth with severe vision loss and nystagmus1. Currently, mutations in 23 genes are known to cause LCA 
(RetNet). The frequency of the disease is about 1 in 50,000. Stargardt disease (STGD) is one of the most frequent 
autosomal recessive macular dystrophy in childhood or adolescence with an estimated incidence of 1 in 10,000. 
Mutations in 4 genes have been reported to cause STGD, with mutations in ABCA4 gene being the most frequent. 
Best macular dystrophy (Best MD) is a stationary or slowly progressing form of macular dystrophy with a variable 
age of onset between childhood and late teenage years. Best MD (due to mutations in BEST1) is most commonly 
inherited in an autosomal dominant manner but autosomal recessive forms have also been reported7. In addition, 
RDs can be either non-syndromic or syndromic (in combination with non-ocular symptoms). Some of the com-
mon syndromic forms are characterized by hearing loss (e.g., Usher syndrome), polydactyly (e.g., Bardet-Biedl 
syndrome, BBS), or renal abnormalities (e.g., Senior–Løken syndrome).
The identification of disease-causing mutations has been tremendously accelerated by implementation of 
next generation sequencing (NGS) technologies in diagnostic genetic testing in familial cases of RDs but also in 
sporadic patients. In this study, we employed whole exome sequencing (WES) in 58 patients with 11 clinically 
different RDs. We were able to identify putative disease causing variants and thus provide a genetic diagnosis in 
64% of the cases. The identified mutation spectrum included novel variants and previously described recurrent 
mutations. Cases and families, where underlying genetic mutations were not identified, might be instrumental for 
the identification of novel disease-associated genes.
Results
Patients. The majority of analyzed patients (n = 58) originated from Switzerland. We cannot however exclude 
that some patients have migrated to Switzerland (24.3% foreigners in Switzerland; Source: http://www.bfs.admin.
ch/). All of the patients were clinically well-defined and included RP (n = 31), STGD (n = 5), LCA (n = 5), 
CORD (n = 3), RD not classified further (n = 3), COD (n = 3), Macular dystrophy (n = 3), Best disease (n = 2), 
Choroideremia (n = 1), BBS (n = 1) and Usher syndrome (n = 1). 38 of these were individual cases with no sam-
ples from additional family members. For the remaining 20 cases, samples from additional family members were 
available to perform segregation analysis.
Whole exome sequencing. HiSeq2000 data: 34 cases were sequenced on the HiSeq2000. 7.2–9.3 Gb of data 
were obtained upon WES that constituted about 9.0*107 reads, with >30 coverage ranging from 81–92% within 
the different sequences. 550–600 variants were obtained within the known RD genes (n = 252) and an average of 
approximately 40,000 variants were obtained with WES. Most of the variants identified were synonymous, closely 
followed by missense variants. A large percentage of the variants lie within the captured intronic regions flanking 
the exons (Fig. 1a, Supplementary Figure 1). A large number of variants obtained were predicted to affect splicing 
by either strongly or weakly activating splice acceptor or donor sites.
NextSeq500 data: 24 cases were sequenced on the NextSeq500. Approximately 12 Gb of data were obtained 
upon WES and 7–9*107 reads, with >20 coverage ranging from 88–93% within the different sequences. The type 
of variants obtained on the NextSeq500 showed a similar trend as obtained on the HiSeq2000. However, the num-
ber of variants obtained was higher with NextSeq500 compared to that of HiSeq2000.
Figure 1a compares the types and numbers of variants obtained within the 252 genes upon sequencing with 
NextSeq500 versus HiSeq2000. Supplementary Figure 1 compares the type and number of variants obtained 
within the entire exome data.
Sequence variants identified in RD cases. We performed WES in 58 cases and identified potentially 
disease-causing variants in known RD genes in 37 (64%) index patients, 25 of whom were simplex/sporadic 
cases. For 13 cases we had samples from additional family members. Figure 1b shows a comparison of the muta-
tion detection rates in various disease phenotypes. A total of 65 mutant alleles were identified in known RD 
genes. While 37 (57%) of these have been previously associated with RD, 28 (43%) are novel variants in known 
RD genes. Amongst the identified disease-associated variants, 24 (36.9%) are missense variants, 18 (27.7%) are 
nonsense variants, 16 (24.6%) are frameshift deletions or insertions and 7 (10.8%) are predicted to affect splic-
ing (Fig. 2a). In our cohort, the majority of variants were identified in ABCA4 (21.54%), followed by C2orf71 
(15.38%) and RP1 (7.69%) and then CEP290, FLVCR1 and CRB1 each contributing 6.15% to the total variants. 
Variants were also identified in 12 additional genes (Fig. 2b)
ABCA4. Mutations in ABCA4 have been previously associated with STGD, RP, MD, COD or CORD pheno-
types1,8,9. In our patient cohort, the majority of variants were identified in ABCA4 (21.54%) (Fig. 2b), which 
included 1 RP, 1 RD, 1 MD, 2 COD and 2 STGD cases (n = 7) (Table 1, Fig. 3a,b). We identified 14 mutant alleles 
in ABCA4, including 2 novel variants. In case 71674, diagnosed with arRD, along with a recurrent nonsense muta-
tion (p.Trp663*, HGMD Accession = CM003370), a novel splice-site variant was identified (c.2160 + 1 G > T) 
(Fig. 3a). This variant is predicted to lead to skipping of exon 14 in the ABCA4 transcript. The patient inherited 
one mutant allele from each parent. A novel missense variant was identified in case 71472 diagnosed with RP 
(Table 1).
C2orf71. Mutations in C2orf71 are known to cause arRP and were first reported by Collen et al. in 201010. Within 
our cohort, mutations in C2orf71 accounted for the second highest number of mutations (15.38%). We identified 
potentially pathogenic variants in C2orf71 in four patients affected with arRP and one diagnosed with CORD 
(Table 1). Almost 50% of the mutations in HGMD described in C2orf71 are truncating mutations. Consistently, 
all the mutations we identified in our patient cohort in C2orf71 are also truncating mutations including three 
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novel variants (p.Trp650*, p.Gly570Glufs*3, p.Leu744Glufs*7). Index patient 29870 and his affected brother 
were diagnosed with RP (Fig. 4a) and carried a homozygous frameshift deletion in C2orf71: NM_001029883.2: 
c.1709_1728del:p.Gly570Glufs*3. This mutation was absent in the unaffected brother. Interestingly, we also iden-
tified the mutation p.Gly570Glufs*3 in two other cases (71703 and 71688) in a compound heterozygous state with 
two additional mutations (Table 1). So far mutations in C2orf71 have been described exclusively for RP. We pres-
ent a novel phenotype for mutations in this gene, leading to cone-rod dystrophy (Case 71703). The affected sibling 
of index 71703 was also diagnosed with CORD and carries the same mutations (data not shown). No additional 
samples from family members were available to perform segregation analysis.
RP1. Mutations in RP1 are known to cause RP and are inherited in autosomal recessive or dominant manner. 
We identified 2 previously described mutations in 4 patients diagnosed with RP (Table 1): a homozygous non-
sense mutation (p.Ser542*, HGMD Accession = CM1211361) in an arRP case; and a heterozygous duplication 
leading to a frameshift (p.Arg872Thrfs*2, HGMD Accession = CI004598), which was identified in three patients 
diagnosed with adRP (Table 1). Index patient 24058 has one affected brother and one unaffected sister. They 
inherited the mutation from their father who had 3 affected brothers and an affected father (Fig. 4b). We also 
identified this mutation in three additional families, which were not part of this study (data not shown). The 
rather high frequency of this mutation in our cohort suggests it to be more abundant in the Swiss population. The 
mutation was absent in 528 control alleles.
CEP290. We identified compound heterozygous mutations in CEP290 in two cases. Index patient 
30421 was diagnosed with LCA, while his parents were unaffected (Fig. 3g). A known frameshift deletion 
Figure 1. (a) Comparison of the numbers and types of variants obtained within 252 genes of interest upon 
sequencing with Illumina NextSeq500 vs HiSeq2000 platforms. (b) Comparison of different disease phenotypes 
and detection rates of pathogenic mutations.
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NM_025114.3:c.6604del:p.Ile2202Leufs* 24 (HGMD Accession = CD072355) was found in 30421. Index patient 
13730 was diagnosed with arRP and has two affected and two unaffected siblings (Fig. 4c). Using WES, a pre-
viously described nonsense mutation was identified in 13730: NM_025114.3:c.5668G>T:p.G1890* (HGMD 
Accession = CM061683). In both cases, the mutations were heterozygous and a mutation in the second allele 
was missing. Since the patients were diagnosed with classical recessive diseases, we wondered if they carried 
a common deep intronic mutation in CEP290. This mutation NM_025114.3:c.2991+1655A>G (HGMD 
Accession = CS064383) accounts for 21–43% of mutations in LCA patients11,12. It leads to an activation of a cryp-
tic splice donor site and inserts a cryptic exon in the messenger RNA of CEP29011,12. Upon Sanger sequencing, we 
were able to confirm this mutation in patients 30421 and 13730. Analyzing the family members, we confirmed 
that patient 30421 inherited one mutant allele from each parent (Fig. 3g). Patient 13730 and her affected brother 
also carried both the mutations, while her unaffected mother was a carrier of the intronic mutation c.2991 + 1655 
A > G (Fig. 4c). It can be assumed that the affected members inherited the nonsense mutation in CEP290 from 
the deceased father, samples from whom were not available.
FLVCR1. We found a novel missense variant in FLVCR1 and a previously described splice-site variant in 2 
patients diagnosed with RP: c.479 T > C (p.Leu160Pro) and c.1092 + 5 G > A (Table 1). The missense variant 
affects a highly conserved amino acid and is classified to be disease-causing by 3 different prediction tools (SIFT, 
PolyPhen2, MutationTaster2). The splice-site variant lies within the consensus splice donor site13 and therefore is 
predicted to affect the normal splicing of exon 4 (Fig. 5a). While case 71315 was compound heterozygous for the 
above variants, case 29303 is homozygous for the c.1092 + 5 G > A variant. Both patients inherited one mutant 
allele respectively from each unaffected parent (Figs 3d,e and 5b,c).
Analysis of FLVCR1 splicing. The effect of the variant (c.1092 + 5 G > A) on the correct splicing of FLVCR1 
has not been studied previously. We extracted total RNA from venous blood of patient 29303 and performed 
reverse transcription-PCR (RT-PCR). We analyzed splicing of exons 1 through 7 and detected two isoforms 
Figure 2. Types and frequencies of sequence variants. (a) Distribution of disease-causing variant types 
within our cohort. (b) Frequencies of gene mutations identified within our cohort in cases where a likely genetic 
diagnosis could be provided.
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S. No. Case No.
Year of 
birth Gender Clinical Diagnosis Gene Mutation (s) Zygosity
HGMD 
Accession
1 71134 1980 M Cone dystrophy ABCA4 NM_000350.2:c.5882G>A:p.Gly1961Glu; NM_000350.2:c.1804C>T:p.Arg602Trp Compound Heterozygous
CM970016 
and 
CM990025
2 71472 1975 F Retinitis pigmentosa ABCA4 NM_000350.2:c.4873C>T:p.His1625Tyr Homozygous This study
3 71522 1990 M Cone dystrophy ABCA4 NM_000350.2:c.5882G>A:p.Gly1961Glu; NM_000350.2:c.5461–10T>C Compound Heterozygous
CM970016 
and CS057513
4 71674 2003 F Retinal dystrophy DD: Retinitis pigmentosa ABCA4
NM_000350.2:c.1988G>A:p.Trp663*; 
NM_000350.2:c.2160+1G>T Compound Heterozygous
CM003370 
and this study
5 71876 1967 F Stargardt disease ABCA4 NM_000350.2:c.5381C>A:p.Ala1794Asp; NM_000350.2:c.2401G>A:p.Ala801Thr Compound Heterozygous
CM990063 
and 
CM070632
6 71927 1989 F Macular dystrophy ABCA4 NM_000350.2:c.5882G>A:p.Gly1961Glu; NM_000350.2:c.2041C>T:p.Arg681* Compound Heterozygous
CM970016 
and 
CM990029
7 71882 1989 M Stargardt disease ABCA4 NM_000350.2:c.6122G>A:p.Gly2041Asp; NM_000350.2:c.5882G>A:p.Gly1961Glu Compound Heterozygous
CM087709 
and 
CM970016
8 70052 1983 M Retinitis pigmentosa C2orf71 NM_001029883.1:c.1949G>A:p.Trp650* Homozygous This study
9 71688 1967 M Retinitis pigmentosa C2orf71 NM_001029883.2:c.947del:p.Asn316Metfs*7; NM_001029883.2:c.1709_1728del:p.Gly570Glufs*3 Compound Heterozygous
CD102940 
and this study
10 29870 1969 F Retinitis pigmentosa C2orf71 NM_001029883.2:c.1709_1728del:p.Gly570Glufs*3 Homozygous This study
11 71703 1991 M Cone-rod dystrophy C2orf71 NM_001029883.2:c.2227_2228del:p.Leu744Glufs*7; NM_001029883.2:c.1709_1728del:p.Gly570Glufs*3 Compound Heterozygous This study
12 71918 1983 F Retinitis pigmentosa C2orf71 NM_001029883.2:c.3002G>A:p.Trp1001* Homozygous CM113611
13 71471 2004 F Retinitis pigmentosa RP1 NM_006269.1:c.1625C>G:p.Ser542* Homozygous CM1211361
14 71728 1959 M Retinitis pigmentosa RP1 NM_006269.1:c.2613dup:p.Arg872Thrfs*2 Heterozygous CI004598
15 28865 1960 M Retinitis pigmentosa RP1 NM_006269.1:c.2613dup:p.Arg872Thrfs*2 Heterozygous CI004598
16 24058 1946 F Retinitis pigmentosa RP1 NM_006269.1:c.2613dup:p.Arg872Thrfs*2 Heterozygous CI004598
17 71192 1977 M Retinal dystrophy RPGR NM_001034853.1:c.2143_2144dup:p.Glu716Glyfs*100 Hemizygous This study
18 71762 2000 F Retinitis pigmentosa RPGR NM_001034853.1:c.2008_2017del:p.Gln670Argfs*24 Heterozygous This study
19 72007 1992 M Retinitis pigmentosa RPGR NM_001034853.1:c.2236_2237del:p.Glu746Argfs*23 Hemizygous CD004113
20 13730 1951 F Retinitis pigmentosa CEP290 NM_025114.3:c.2991+1655A>G; NM_025114.3:c.5668G>T:p.Gly1890* Compound Heterozygous
CS064383 and 
CM061683
21 30421 2008 M Leber Congenital Amaurosis CEP290
NM_025114.3:c.2991+1655A>G; 
NM_025114.3:c.6604del:p.Ile2202Leufs*24 Compound Heterozygous
CS064383 and 
CD072355
22 71315 2006 M Retinitis pigmentosa FLVCR1 NM_014053.2:c.1092 + 5G>A; NM_014053.2:c.479T>C:p.Leu160Pro Compound Heterozygous
CS140551 and 
this study
23 29303 1979 F Retinitis pigmentosa FLVCR1 NM_014053.2:c.1092 + 5G>A Homozygous CS140551
24 71133 2011 F Leber Congenital Amaurosis CRB1 NM_201253.2:c.2230C>T:p.Arg744* Homozygous This study
25 71161 2009 F Leber Congenital Amaurosis CRB1
NM_201253.2:c.547T>C:p.Cys183Arg; 
NM_201253.2:c.2687G>C:p.Cys896Ser Compound Heterozygous This study
26 70946 1980 F Best macular dystrophy BEST1 NM_001139443.1:c.404C>T:p.Ala135Val Homozygous CM004430
27 70559 1991 M Best macular dystrophy BEST1 NM_001139443.1:c.548C>T:p.Ala183Val Heterozygous CM000841
28 71583 1971 F Retinal dystrophy FAM161A NM_001201543.1:c.1807G>T:p.Glu603* Homozygous This study
29 71749 1990 F Retinitis pigmentosa USH2A NM_206933.2:c.15020C>T:p.Pro5007Leu; NM_206933.2:c.8522G>A:p.Trp2841* Compound Heterozygous This study
30 30806 1998 F Bardet-Biedl Syndrome BBS2 NM_031885.3:c.1237C>T:p.Arg413*; NM_031885.3:c.241G>T:p.Gly81Cys Compound Heterozygous
CM033336 
and 
CM114523
31 27419 1992 M Usher syndrome HARS NM_002109.5:c.410G>A:p.Arg137Gln; NM_002109.5:c.262G>A:p.Gly88Ser Compound Heterozygous
CM130192 
and this study
32 25939 1978 M Retinitis pigmentosa PDE6B NM_000283.3:c.810C>A:p.Cys270*; NM_000283.3:c.811G>A:p.Glu271Lys Compound Heterozygous
CM962548 
and this study
33 71868 2003 M Retinitis pigmentosa DD: Retinal dystrophy RDH12
NM_152443.2:c.193C>T:p.Arg65*; 
NM_152443.2:c.806_810del:p.Ala269Glyfs*2 Compound Heterozygous
CM054831 
and 
CD042224
34 71808 1960 M Retinitis pigmentosa EYS NM_001292009.1:c.8713T>G:p.Cys2905Gly; NM_001292009.1:c.8269G>C: p.Ala2757Pro Compound Heterozygous This study
35 71094 1974 M Cone-rod dystrophy PROM1 NM_006017.2:c.380G>A:p.Gly127Glu Homozygous This study
36 71718 1983 F Stargardt disease ELOVL4 NM_022726.3:c.810C>G:p.Tyr270* Heterozygous CM045143
37 71780 1979 M Macular dystrophy RP1L1 NM_178857.5:c.1138G>A:p.Gly380Arg Heterozygous This study
Table 1.  Overview of the 37 cases with clinical diagnosis and most likely disease-causing variants. DD: 
Differential diagnosis.
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exclusively in the patient: one PCR product of expected size and a second shorter product (Fig. 5d). Upon 
sequencing of these products, we confirmed that the shorter product lacked exon 4 (Fig. 5e). Exon 4 skipping is 
highlighted in yellow in the sequence alignment of FLVCR1 sequences generated from the patient and the ref-
erence (Fig. 5e). In contrast, RT-PCR done from control RNA showed normal splicing (Fig. 5d,f). These results 
clearly show that the variant c.1092 + 5 A > G causes exon skipping from the pre-mRNA by interfering with the 
correct splicing of FLVCR1. Skipping of exon 4 is predicted to introduce a frameshift deletion of 68 base-pairs 
and consequently a premature termination codon in the mRNA, 31 triplets downstream of Ile343. This truncated 
mRNA most likely will be targeted for nonsense mediated decay.
RPGR. We detected three frameshift deletions in RPGR two of which are novel (p.Glu716Glyfs*100 and 
p.Gln670Argfs*24) (Table 1). The female index patient 71762 and her father were diagnosed with RP, but not 
her mother (Fig. 3c). The pedigree looked like a classic case of autosomal dominant RP. Sanger screening of the 
most common adRP associated genes RHO, PRPF31, RP1 and PRPH2 did not detect a pathogenic mutation. With 
WES we observed a novel heterozygous 10 base-pair deletion in RPGR (NM_001034853.1:c.2008_2017del:p.
Gln670Argfs*24) that leads to a frameshift followed by truncation of the transcript, 24 triplets downstream of the 
mutation. Mutations in RPGR have been associated with complete expression of disease phenotype in hemizy-
gous males and incomplete or variable expression in heterozygous carrier females14.
HARS. Mutations in this gene have recently been associated with Usher syndrome15,16. Index patient 27419 was 
diagnosed with Usher syndrome with no family history for the disease. We identified compound heterozygous 
missense variants in HARS: (i) NM_002109.5:c.262G>A:p.Gly88Ser (Novel) (ii) NM_002109.5:c.410G>A:p.
Arg137Gln. This variant has been previously associated with peripheral neuropathy (HGMD accession: 
CM130192). Both variants substitute highly conserved amino acid residues (from Baker’s yeast to human) and are 
predicted to be disease-causing by three prediction programs (SIFT, MutationTaster2, Polyphen2). The variants 
cosegregated in the family (Fig. 4d).
Figure 3. Segregation analysis of disease-causing variants. Index patients are marked with an arrow. All 
affected individuals are indicated with filled squares or circles.
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Other genes. We found three novel variants in CRB1 (p.Arg744*, p.Cys183Arg, p.Cys896Ser) in two LCA 
patients. We also detected recurrent mutations in BEST1: homozygous p.Ala135Val and heterozygous 
p.Ala183Val. Mutations in BEST1 are known to be inherited in a recessive or dominant fashion. Two novel var-
iants in USH2A (p.Pro5007Leu and p.Trp2841*) were also identified in a patient diagnosed with RP. We also 
observed novel and recurrent variants in PDE6B, RDH12, EYS, PROM1, ELOVL4 and RP1L1 (Table 1).
Cases where disease-causing variants were not identified. In 36% of our cases, we were not able to identify the 
underlying genetic cause of the disease.
Discussion
We contributed to a recent report describing a panel-based NGS approach of retinal genes17. Targeted sequencing 
of known genes has been successfully employed to identify disease-causing mutations in inherited RDs with var-
iable rates of success between 60% for non-syndromic cases (e.g, RP) and 80% in syndromic cases17. Therefore, 
although very efficient, panel-based sequencing has its limitations. In cases where no disease-associated variants 
are identified within genes that have been included in the panel, other approaches have to be used to identify the 
genetic basis of the disease, which adds to costs and time. With 20–40% cases lacking a genetic diagnosis, the costs 
are significantly higher for a gene diagnostics laboratory and this may in turn lead to significantly higher costs 
for patients, when genetic testing is not covered by health insurance. In addition, with new genes being rapidly 
associated to various forms of RDs, modifying the panel becomes expensive. Therefore, we performed WES in 
our patients, which has the potential of identification of novel disease-associated genes. To our knowledge, this 
is the first report with WES data generated from human RD cases using NextSeq500. Variant distribution was 
comparable between both HiSeq2000 and NextSeq500 platforms; however we obtained slightly higher numbers 
of variants with NextSeq500. A possible reason could be the difference in the chemistries of the two platforms and 
the different bioinformatic algorithms used to analyze the generated data.
In this study we performed WES in 58 cases diagnosed with various RDs. Most of the patients were of Swiss 
origin. Wherever possible, samples from additional family members were included to perform segregation anal-
ysis. We used a stringent filtering approach that included assessment of multiple parameters such as frequency of 
the variants, their effect on the encoded protein, and thorough literature search for previously described variants. 
We identified the underlying genetic basis for the various diseases in 64% of the cases, which is comparable to 
Figure 4. Segregation analysis of disease-causing variants. Index patients are marked with an arrow. All 
affected individuals are indicated with filled squares or circles.
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previously reported panel-based approaches17,18 and sometimes even higher19. In addition to 26 recurrent muta-
tions that have been previously associated with RDs, we detected 20 novel variants that expand the spectrum of 
mutations causing RDs. Amongst the 20 novel variants identified, 11 are missense variations, while others are 
loss of function nonsense or frameshift alterations including one variant affecting splicing. Although the bioin-
formatic algorithms for prediction of missense variants have their limitation, they are accepted as a first attempt 
to interpret pathogenic relevance of amino acid substitutions. Finally, only functional assays for the respective 
proteins can provide conclusive evidence. We also present novel phenotypes for known disease-associated genes, 
thus expanding the clinical spectrum of mutations in these genes, which is of relevance for future gene diagnostics 
in RD patients.
Within our patient cohort, the majority of variants were identified in ABCA4, followed by C2orf71 and 
RP1. Mutations in ABCA4 are predominantly known to cause STGD (currently 610 mutations in ABCA4 
Figure 5. DNA and RNA analysis of the FLVCR1 mutation c.1092 + 5G > A. (a) Partial gene structure of 
FLVCR1 is displayed in a schematic drawing. Position of the mutation is indicated with an arrow. This mutation 
is predicted to affect the canonical splice donor site of exon 4 in FLVCR1. (b) Sanger sequence of patient DNA 
showing homozygous mutation c.1092 + 5G > A in FLVCR1. (c) Sanger sequence of DNA from patient’s mother 
showing heterozygous mutation c.1092 + 5G > A in FLVCR1. Father of the patient was also heterozygous 
(data not shown). (d) Agarose gel image of RT-PCR products from blood RNA. An unrelated, and unaffected 
individual was used as control. While patient and control both show a product of expected size, the patient 
sample shows an additional shorter band indicating skipping of exon 4. This was verified by sequencing of both 
products. (e) Alignment of FLVCR1 cDNA sequence obtained from the patient in comparison to reference 
showing the skipping of exon 4 (highlighted in yellow). (f) Alignment of the FLVCR1 cDNA sequence from the 
control sample in comparison to reference showing no skipping of exon 4.
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have been associated with STGD, source: HGMD), however mutations in ABCA4 are also associated with RP 
and CORD1,8,9. Although mutations in EYS seem to account for the majority of autosomal recessive RP cases 
(source: HGMD), in our cohort we identified EYS variants in only one case. Similarly, compared to mutations 
in known disease-associated genes in RD (data not shown; source: HGMD), variants in USH2A, CRB1 and 
PDE6B were under-represented in our dataset, while mutations in C2orf71, FLVCR1 and CEP290 were more 
frequent in Swiss RD patients. This difference in the frequencies of variants known to be RD-associated could be 
population-specific, also keeping into account the migration background within the Swiss population.
Since its first association with RP in 2010 by Collin et al.10, 29 mutations have been identified in C2orf71 that 
lead to arRP (source: HGMD). We identified a novel 20 base-pair frameshift deletion in the C2orf71 gene (NM_0
01029883.2:c.1709_1728del:p.Gly570Glufs*3) in three of our patients, either in compound heterozygous (71688, 
71703) or homozygous state (29870) (Fig. 4a, Table 1). We have identified this mutation in patient 71703 and his 
affected brother, both of whom were diagnosed with CORD. This presents a novel disease phenotype associated 
with mutations in C2orf71. There is one report which associates mutations in C2orf71 with CORD type of arRP20, 
but not a true CORD phenotype.
A previous study, to which we contributed, had identified a variant in FLVCR1 (NM_014053.2:c.1092+5G>A) 
in a RP patient17. Since this variant lies within the highly conserved splice donor consensus sequence at position 
+5 from the 3’-end of exon 4 in FLVCR1, a defect in splicing is very likely. We performed RT-PCR experiments to 
evaluate the effect of the variant c.1092 + 5 G > A on the splicing of the FLVCR1 messenger RNA and found that 
the variant leads to skipping of exon 4 (Fig. 5). In addition, mutations in the FLVCR1 gene have been associated 
with posterior column ataxia with retinitis pigmentosa (PCARP). In both our patients described above (71315 
and 29303), no posterior column ataxia phenotype was reported until the last clinical examination. FLVCR1 
associated posterior column ataxia has been reported to manifest in the second decade of life21. Although the first 
patient (71315) is rather young (9 years of age), the second patient 29303 (36 years of age) has not shown any signs 
of neurologic disorders (until the last clinical examination done at the age of 34). It is difficult to comment on 
whether this might be a novel phenotype associated with mutations in FLVCR1. Alternatively, some copies of cor-
rectly spliced mRNA could be retained despite the homozygous splice-site variant in patient 29303, which might 
be sufficient to prevent extraocular neurological symptoms, but only leads to a retinal phenotype. Pathological 
significance of this exon 4 skipping is currently being studied in our laboratory in more detail. To delineate 
whether the two patients could be related, we compared informative SNPs which are close to the causative variant 
in both cases (c.1092 + 5 G > A of FLVCR1 gene). Since virtually all of the flanking SNPs were heterozygous, even 
in case 29303 (in whom the FLVCR1 variant c.1092 + 5 G > A is homozygous), two independent mutation events 
at the two different alleles are considered more likely. Otherwise, if the mutation would be derived from the same 
ancestral allele or haplotype, we also should observe homozygosity for SNPs flanking this variant.
In the family of case 71762, an apparent adRP revealed an X-linked inheritance pattern upon WES. The 
female index patient inherited from her father a pathogenic frameshift deletion mutation in RPGR on one allele. 
X-inactivation of the normal allele could be the most likely possibility for expression of the disease phenotype, as 
has been reported in earlier studies in case of RPGR14,22.
Using linkage analysis and exome sequencing, Puffenberger et al. reported a homozygous mutation in the 
HARS gene in patients of Swiss origin affected with Usher syndrome15. Mutations in HARS have also been asso-
ciated with peripheral neuropathies. In case 27419 diagnosed with Usher syndrome, we identified compound 
heterozygous missense variants in HARS. Variant c.262 G > A:p.Gly88Ser was novel while the second mutation 
c.410 G > A:p.Arg137Gln has been shown to cause loss of function using yeast complementation assays and was 
associated with peripheral neuropathy23. However, this patient has not shown any signs of neurological disorders 
until the last clinical examination. Upon an initial screening with fewer genes of interest, we had not identi-
fied disease associated variants in this case. Only upon the association of the HARS gene with Usher syndrome, 
we searched for variants in Usher syndrome cases in our cohort and identified compound heterozygous patho-
genic variants in HARS gene in this case. This case highlights the advantage of using WES in comparison with 
panel-based NGS.
Cases 30421 and 13730 highlight the limitations of WES. In both cases we identified heterozygous pathogenic 
mutations in CEP290 on one allele only. The second mutant allele could not be identified by exome capturing 
methods as it was located in a deep intronic region (c.2991 + 1655 A > G)11,12. This represents a strong case for 
complementing exome sequencing with other methods such as whole genome sequencing or Sanger sequencing 
for specific mutations.
Detection of multiple disease-associated variants in single patients. Most of our patients carried 
additional variants in known RD genes that either did not fit the inheritance pattern (e.g. only one recessive var-
iant in an RD-associated gene), or did not pass one of the filtering criteria. The effect of such additional variants 
is difficult to predict, but these could act as disease modifiers, leading to an earlier or delayed onset/progression 
of the disease. A list of these variants has been added in supplementary Table 1. These variants were chosen to be 
pathogenic based on the same criteria that were used to identify disease associated variants.
In conclusion, we have established a highly efficient and reliable whole-exome sequencing and data analysis 
pipeline that delivers a high diagnostic yield of approximately 65%. In addition, WES provides the advantage 
that datasets can be reanalyzed as soon as a novel gene for RDs is reported. Wherever possible, we have included 
additional family members to confirm the diagnosis, an approach which is essential given the fact that patients 
frequently carry more than one pathogenic mutation in their genome. We have also detected a significant number 
of novel variants that will aid in further characterizing disease pathogenicity, in addition to identifying novel 
phenotypes for genes previously associated to some form of RD.
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Materials and Methods
Patients and families. Patients and family members were referred to us from the eye clinics at the University 
Hospital Zürich and University Hospital Bern for genetic testing purposes. All patients or family members as well 
as parents of affected children provided informed consent for genetic testing according to Swiss laws. The clinical 
diagnosis was established by a comprehensive ophthalmological examination, functional electroretinography 
(ERG) and morphological studies (optical coherence tomography, OCT; fluorescein angiography, FAG; autoflu-
orescence imaging, AF).
The study was conducted in accordance with the Helsinki Declaration. The approval for genetic testing 
was awarded to The Institute of Medical Molecular Genetics by the Federal Office of Public Health (FOPH) in 
Switzerland.
DNA extraction. Genomic DNA was isolated from patients’ blood samples according to the manufacturer’s 
recommendations using a coated magnetic bead technology (PerkinElmer Chemagen Technologie GmbH, 
Baesweiler, Germany). DNA quantification was performed using the Nanodrop (Life technologies, Darmstadt, 
Germany).
Whole exome sequencing (WES). WES was performed either at Atlas Biolabs (Berlin, Germany) using 
Illumina HiSeq2000 or in-house using Illumina NextSeq500. Sequencing with HiSeq2000 and bioinformatics 
analysis was done as previously described24. For sequencing at the NextSeq500 platform, libraries were generated 
using Nextera Rapid Capture Exome (Illumina) to generate 150 bp paired-end reads. Alignment of sequence 
reads, indexing of the reference genome, variant calling and annotation was done with a pipeline based on BWA 
using BaseSpace Onsite (Illumina). Variants were annotated using Alamut-HT and visualized on Alamut Viewer 
2.2 (Interactive Biosoftware, Rouen, France). A filtering pipeline was established to identify the most likely 
disease-causing variant. Since RDs are rare in the population, only variants with frequency below 1% were chosen. 
Frequencies of identified variants were also cross-verified on Exome Sequencing Project (ESP) data and Exome 
Aggregation Consortium (ExAC) data. Mutations that have been previously described to be disease-causing in 
Human Gene Mutation Database (HGMD) and literature were given the highest priority. The effect of mutations 
that were described in HGMD were further validated by reading published literature reporting the variants and 
only those variants that had convincing evidence were chosen. In addition, protein truncation mutations such 
as nonsense and frameshift (insertions or deletions), were also ranked higher in priority. For variants leading to 
amino acid substitution, pathogenicity predictions from five programs namely SIFT25, MAPP26, AGVGD27,28, 
MutationTaster229 and Polyphen230 were compared.
To make sure that medically and diagnostically important variants are not being missed, the following 
approach was used for cases where no disease-associated variants were identified:
 (i)  Genes that have been most frequently associated with a certain disease subtype or inheritance pattern were 
manually screened on Alamut-viewer to check for coverage and variants that could have been missed by the 
variant caller. For example in patients with Leber congenital amaurosis (LCA) or Usher syndrome, exons of 
all genes described in Retnet to be associated with LCA or Usher were carefully screened manually.
 (ii)  If an exon was identified that was not covered and in which known variants have been identified and are 
included in HGMD, we Sanger sequenced these uncovered exons.
(iii)  For recessive cases, if we identified a pathogenic heterozygous variant in one or more of the 252 genes, we 
screened all exons of these genes. We Sanger sequenced any poorly covered (<10× coverage) or uncovered 
exons of these genes in order to make sure that a second variant is not being missed.
RPGR OFR15. RPGR ORF15 is often poorly covered by NGS capture methods due to its repetitive nature. 
Patients with RPGR mutations show a severe early onset RP phenotype. All male patients diagnosed with an early 
onset (age <20 years) and severe RP phenotype were screened for RPGR ORF15 by conventional Sanger sequenc-
ing in our laboratory31.
Primer design, PCR amplification and Sanger sequencing. Primer design, PCR and Sanger sequencing 
was performed as previously described24. Sanger sequencing data analysis was performed using the Sequencing 
Analysis Software v5.4, Sequence Pilot (JSI Medical Systems, Germany) and SeqScape v2.6 (Applied Biosystems, 
Carlsbad, California, USA) to identify the likely disease causing variants. Mutation is defined as previously 
described17.
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